GEORGIA STATUTES AND CODES
               		§ 26-4-171 - Definitions
               		
               		
               	 	
               	 	               	 	
               	 	
               	 	
               	 		
O.C.G.A.    26-4-171   (2010)
   26-4-171.    Definitions 
      As used in this article, the term:
      (1)  "Authentication  of product history" means, but is not limited to, identifying the  purchasing source, the ultimate fate, and any intermediate handling of  any component of a radiopharmaceutical.
      (2)  "Board" means the State Board of Pharmacy.
      (3)  "Compounding  of radiopharmaceuticals" means the addition of a radioactive substance  to nonradioactive substances or the use of a radioactive substance in  preparation for single or multidose dispensation upon the prescription  order of a physician who is licensed to use radioactive materials.  Compounding of radiopharmaceuticals may include: loading and eluting of  radionuclide generators; using manufactured reagent kits to prepare  radiopharmaceuticals; preparing reagent kits; aliquoting reagents;  formulation and quality assurance testing of radiochemicals for use as  radiopharmaceuticals; and radiolabeling of compounds or products,  including biological products, for use as radiopharmaceuticals.
      (4)  "Department" means the Department of Natural Resources.
      (5)  "Internal  test assessment" means, but is not limited to, conducting those tests  of quality assurance necessary to ensure the integrity of the test.
      (6)  "Manufacturing  of radiopharmaceuticals" means the preparation, derivation, or  production of a product to which a radioactive substance is or will be  added to provide a radiopharmaceutical for sale, resale, redistribution,  or reconstitution.
      (7)  "Nuclear pharmacy" means a pharmacy providing radiopharmaceutical service.
      (8)  "Radiopharmaceutical"  means radioactive drugs and chemical products used for diagnostic and  therapeutic purposes and includes the terms radioactive pharmaceuticals,  radioisotopes, and radioactive tracers.
      (9)  "Radiopharmaceutical  quality assurance" means, but is not limited to, the performance of  appropriate chemical, biological, and physical tests on  radiopharmaceuticals and their component materials and the  interpretation of the resulting data to determine their suitability for  use in humans and animals, including internal test assessment,  authentication of product history, and the keeping of proper records.
      (10)  "Radiopharmaceutical  service" means, but is not limited to, the compounding, dispensing,  labeling, and delivering of radiopharmaceuticals; the participation in  radiopharmaceutical selection and radiopharmaceutical utilization  review; the maintenance of radiopharmaceutical quality assurance; and  the responsibility for advising, where necessary or where regulated, of  therapeutic values, hazards, and use of radiopharmaceuticals; and the  offering or performing of those acts, services, operations, or  transactions necessary in the conduct, operation, management, and  control of a nuclear pharmacy.